GALWAY, Ireland–(BUSINESS WIRE)–Vivasure Medical®, a company pioneering novel fully absorbable technology for percutaneous vessel closure, today announced the European launch of the PerQseal® closure device for large-bore transcatheter procedures. Novel transcatheter endovascular procedures, including transcatheter aortic valve replacement (TAVR), thoracic endovascular aneurysm repair (TEVAR), and endovascular abdominal aneurysm repair (EVAR), require […]
Author: Ken Dropiewski
AtriCure to Present at the Piper Jaffray 30th Annual Healthcare Conference
MASON, Ohio–(BUSINESS WIRE)–AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that it will present at the Piper Jaffray 30thAnnual Healthcare Conference in New York City on Wednesday, November 28. Management is scheduled to present at 8:00 a.m. Eastern […]
Silk Road Medical Announces Key TCAR Presentations at 2018 VEITHsymposium
SUNNYVALE, Calif.–(BUSINESS WIRE)–Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, today announced that multiple podium presentations at the upcoming VEITHsymposium Nov. 13-17 at the New York Hilton-Midtown will feature the company’s TransCarotid Artery Revascularization (TCAR) procedure. One-year results from the Society […]
BioCardia Reports Third Quarter 2018 Financial Results and Business Highlights
SAN CARLOS, Calif.–(BUSINESS WIRE)–BioCardia®, Inc. [OTC: BCDA], a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today reported financial results and business highlights for the third quarter 2018 and filed its quarterly report on Form 10-Q for the three and nine months ended September 30, 2018 with the […]
InCarda Therapeutics Provides Corporate Update Highlighting Fundraising and Clinical Development Milestones
SAN FRANCISCO, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) — InCarda Therapeutics, Inc. (“InCarda”), a privately-held biopharmaceutical company developing first-of-their-kind inhaled therapies for cardiovascular diseases, today provided a corporate update highlighting fundraising and clinical development milestones. These achievements have contributed to the continued successful development of its lead clinical program, while […]
BioTelemetry, Inc. Elects Stephan Rietiker to its Board of Directors
MALVERN, Pa., Nov. 07, 2018 (GLOBE NEWSWIRE) — BioTelemetry, Inc. (NASDAQ:BEAT) announced today that Stephan Rietiker has been elected to BioTelemetry’s Board of Directors. Dr. Rietiker was most recently the Chief Executive Officer of LifeWatch AG, until it was acquired by BioTelemetry in August 2017. Prior to becoming CEO of […]
Amarin to Present at the Jefferies 2018 London Healthcare Conference
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 08, 2018 (GLOBE NEWSWIRE) — Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thero, Amarin’s president and chief executive officer, is scheduled to present a general company update at […]
Orchestra BioMed™ Announces AHA 2018 Presentation on BackBeat® Cardiac Neuromodulation Therapy (CNT)
NEW HOPE, Pa., Nov. 08, 2018 (GLOBE NEWSWIRE) — Orchestra BioMed, Inc., (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that Professor Petr Neuzil, M.D., Head of the Department of Cardiology of Na Homolce Hospital in Prague, Czech […]
CHF Solutions to Release Educational Webinar Highlighting Use of Aquadex FlexFlow® System in Post-Cardiovascular Surgery Featuring Noted Cardiovascular Surgeon, Daniel Beckles, MD, PhD
EDEN PRAIRIE, Minn., Nov. 08, 2018 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS), today announced that it will release an educational webinar featuring the clinical use of the Aquadex FlexFlow system following cardiovascular surgery in patients who have failed diuretic therapy. The webinar will be viewable on the company’s […]
MEDTRONIC BEGINS RENAL DENERVATION STUDY FOR HIGH BLOOD PRESSURE PATIENTS PRESCRIBED ANTI-HYPERTENSIVE MEDICATION
DUBLIN – November 8, 2018 – Medtronic plc (NYSE:MDT) today announced U.S. Food and Drug Administration (FDA) approval to begin a clinical trial to evaluate the Symplicity Spyral(TM) renal denervation system in patients with high blood pressure (hypertension) who are already prescribed anti-hypertension medications. The SPYRAL HTN-ON MED Trial is the […]



